These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

187 related items for PubMed ID: 30719772

  • 1. Pomalidomide-dexamethasone for treatment of soft-tissue plasmacytomas in patients with relapsed / refractory multiple myeloma.
    Jiménez-Segura R, Granell M, Gironella M, Abella E, García-Guiñón A, Oriol A, Cabezudo E, Clapés V, Soler JA, Escoda L, López-Pardo J, Fernández de Larrea C, Cibeira MT, Tovar N, Isola I, Bladé J, Rosiñol L, GEMMAC (Grup per l l'estudi del mieloma mútiple i l'amiloïdosi de Catalunya).
    Eur J Haematol; 2019 May; 102(5):389-394. PubMed ID: 30719772
    [Abstract] [Full Text] [Related]

  • 2. Refractory plasmablastic type myeloma with multiple extramedullary plasmacytomas and massive myelomatous effusion: remarkable response with a combination of thalidomide and dexamethasone.
    Nakazato T, Suzuki K, Mihara A, Sanada Y, Kakimoto T.
    Intern Med; 2009 May; 48(20):1827-32. PubMed ID: 19834276
    [Abstract] [Full Text] [Related]

  • 3. Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone.
    Dimopoulos MA, Weisel KC, Song KW, Delforge M, Karlin L, Goldschmidt H, Moreau P, Banos A, Oriol A, Garderet L, Cavo M, Ivanova V, Alegre A, Martinez-Lopez J, Chen C, Spencer A, Knop S, Bahlis NJ, Renner C, Yu X, Hong K, Sternas L, Jacques C, Zaki MH, San Miguel JF.
    Haematologica; 2015 Oct; 100(10):1327-33. PubMed ID: 26250580
    [Abstract] [Full Text] [Related]

  • 4. Analysis of renal impairment in MM-003, a phase III study of pomalidomide + low - dose dexamethasone versus high - dose dexamethasone in refractory or relapsed and refractory multiple myeloma.
    Weisel KC, Dimopoulos MA, Moreau P, Lacy MQ, Song KW, Delforge M, Karlin L, Goldschmidt H, Banos A, Oriol A, Alegre A, Chen C, Cavo M, Garderet L, Ivanova V, Martinez-Lopez J, Knop S, Yu X, Hong K, Sternas L, Jacques C, Zaki MH, San Miguel J.
    Haematologica; 2016 Jul; 101(7):872-8. PubMed ID: 27081177
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. The European medicines agency review of pomalidomide in combination with low-dose dexamethasone for the treatment of adult patients with multiple myeloma: summary of the scientific assessment of the committee for medicinal products for human use.
    Hanaizi Z, Flores B, Hemmings R, Camarero J, Sancho-Lopez A, Salmonson T, Gisselbrecht C, Laane E, Pignatti F.
    Oncologist; 2015 Mar; 20(3):329-34. PubMed ID: 25673103
    [Abstract] [Full Text] [Related]

  • 7. Safe and prolonged survival with long-term exposure to pomalidomide in relapsed/refractory myeloma.
    Fouquet G, Pegourie B, Macro M, Petillon MO, Karlin L, Caillot D, Roussel M, Arnulf B, Mathiot C, Marit G, Kolb B, Stoppa AM, Brechiniac S, Richez V, Rodon P, Banos A, Wetterwald M, Garderet L, Royer B, Hulin C, Benbouker L, Decaux O, Escoffre-Barbe M, Fermand JP, Attal M, Avet-Loiseau H, Moreau P, Facon T, Leleu X, IFM (Intergroupe Francophone du Myélome).
    Ann Oncol; 2016 May; 27(5):902-7. PubMed ID: 26787238
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. [A clinical analysis of 25 cases of multiple myeloma complicated by extramedullary plasmacytomas].
    Zhong YP, Chen SL.
    Zhonghua Nei Ke Za Zhi; 2009 May; 48(5):396-8. PubMed ID: 19615158
    [Abstract] [Full Text] [Related]

  • 12. Rapid response of plasmacytomas to lenalidomide plus low-dose dexamethasone therapy in a patient with relapsed multiple myeloma.
    Fukushima T, Nakamura T, Iwao H, Umehara H.
    Am J Hematol; 2011 Oct; 86(10):893. PubMed ID: 21812018
    [No Abstract] [Full Text] [Related]

  • 13. Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma.
    Dimopoulos MA, Dytfeld D, Grosicki S, Moreau P, Takezako N, Hori M, Leleu X, LeBlanc R, Suzuki K, Raab MS, Richardson PG, Popa McKiver M, Jou YM, Shelat SG, Robbins M, Rafferty B, San-Miguel J.
    N Engl J Med; 2018 Nov 08; 379(19):1811-1822. PubMed ID: 30403938
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Pomalidomide and Low-Dose Dexamethasone Improves Health-Related Quality of Life and Prolongs Time to Worsening in Relapsed/Refractory Patients With Multiple Myeloma Enrolled in the MM-003 Randomized Phase III Trial.
    Weisel K, Dimopoulos M, Song KW, Moreau P, Palumbo A, Belch A, Schey S, Sonneveld P, Sternas L, Yu X, Amatya R, Gibson CJ, Zaki M, Jacques C, San Miguel J.
    Clin Lymphoma Myeloma Leuk; 2015 Sep 08; 15(9):519-30. PubMed ID: 26149712
    [Abstract] [Full Text] [Related]

  • 17. Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations.
    Rosiñol L, Beksac M, Zamagni E, Van de Donk NWCJ, Anderson KC, Badros A, Caers J, Cavo M, Dimopoulos MA, Dispenzieri A, Einsele H, Engelhardt M, Fernández de Larrea C, Gahrton G, Gay F, Hájek R, Hungria V, Jurczyszyn A, Kröger N, Kyle RA, Leal da Costa F, Leleu X, Lentzsch S, Mateos MV, Merlini G, Mohty M, Moreau P, Rasche L, Reece D, Sezer O, Sonneveld P, Usmani SZ, Vanderkerken K, Vesole DH, Waage A, Zweegman S, Richardson PG, Bladé J.
    Br J Haematol; 2021 Aug 08; 194(3):496-507. PubMed ID: 33724461
    [Abstract] [Full Text] [Related]

  • 18. Thalidomide in combination with cyclophosphamide and dexamethasone (thacydex) is effective in soft-tissue plasmacytomas.
    González-Porras JR, González M, García-Sanz R, San Miguel JF.
    Br J Haematol; 2002 Dec 08; 119(3):883-4. PubMed ID: 12437681
    [No Abstract] [Full Text] [Related]

  • 19. Salvage therapy post pomalidomide-based regimen in relapsed/refractory myeloma.
    Fouquet G, Karlin L, Macro M, Caillot D, Roussel M, Arnulf B, Pegourie B, Petillon MO, Mathiot C, Hulin C, Kolb B, Stoppa AM, Brechiniac S, Rodon P, Dib M, Tiab M, Richez V, Araujo C, Wetterwald M, Garderet L, Royer B, Perrot A, Benboubker L, Decaux O, Escoffre-Barbe M, Fermand JP, Moreau P, Avet-Loiseau H, Attal M, Facon T, Leleu X.
    Ann Hematol; 2018 May 08; 97(5):831-837. PubMed ID: 29330561
    [Abstract] [Full Text] [Related]

  • 20. Overall survival of relapsed and refractory multiple myeloma patients after adjusting for crossover in the MM-003 trial for pomalidomide plus low-dose dexamethasone.
    Morgan G, Palumbo A, Dhanasiri S, Lee D, Weisel K, Facon T, Delforge M, Oriol A, Zaki M, Yu X, Sternas L, Jacques C, Akehurst R, Offner F, Dimopoulos MA.
    Br J Haematol; 2015 Mar 08; 168(6):820-3. PubMed ID: 25403264
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.